ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Viatris, Pfizer and Yuhan side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Viatris×Pfizer×Yuhan×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

ViatrisPfizerYuhan
studies on the registry7784,073174
open to participants now914735
phase 3 studies under way6995
reach primary completion within a year89210
programswith a study of their own in two years691+9 named only53

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseViatrisPfizerYuhan
Phase 100%

Pfizer: 42 of its 91 programs at phase 1

  1. polfurmetinibphase 1
  2. claturafenibphase 1
  3. PF-07985631phase 1
  4. PF-08642534phase 1
  5. Anti-integrin Beta-6 Antibody-drug Conjugate PF-08046876phase 1

and 37 more — sign in to see them all

46%

Yuhan: 45 of its 53 programs at phase 1

  1. AD-1161phase 1
  2. AD-116Aphase 1
  3. AD-118phase 1
  4. AD-230phase 1
  5. PA-111phase 1

and 40 more — sign in to see them all

85%
Phase 2

Viatris: 1 of its 6 programs at phase 2

  1. MR-130A-01phase 2
17%

Pfizer: 10 of its 91 programs at phase 2

  1. PF-07328948phase 2
  2. tegtociclibphase 2
  3. PF-08653945phase 2
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 5 more — sign in to see them all

11%

Yuhan: 3 of its 53 programs at phase 2

  1. AD-211phase 2
  2. lesigerceptphase 2
  3. YH32364phase 2
6%
Phase 3

Viatris: 2 of its 6 programs at phase 3

  1. cenerimodphase 3
  2. selatogrelphase 3
33%

Pfizer: 31 of its 91 programs at phase 3

  1. berobenatidephase 3
  2. tivunatamigphase 3
  3. tilrekimigphase 3
  4. ritlecitinibphase 3
  5. abrysvophase 3

and 26 more — sign in to see them all

34%

Yuhan: 5 of its 53 programs at phase 3

  1. AD-227Bphase 3
  2. AD-233Aphase 3
  3. AD-233Bphase 3
  4. AD-2282phase 3
  5. YHP2401phase 3
9%
Approved, new studies

Viatris: 3 of its 6 programs at approved, new studies

  1. Gabapentinapproved, new study
  2. Alprazolamapproved, new study
  3. Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionateapproved, new study
50%

Pfizer: 8 of its 91 programs at approved, new studies

  1. rimegepantapproved, new study
  2. tucatinibapproved, new study
  3. elranatamabapproved, new study
  4. tisotumab vedotinapproved, new study
  5. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineapproved, new study

and 3 more — sign in to see them all

9%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Viatris4 readouts · 3 phase 3

Viatris, Nov ’26: 1 program whose next study reaches primary completion

  1. MR-130A-01phase 2 · Nov 30 · NCT07365904

Viatris, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. cenerimodphase 3 · Dec 31 · NCT05672576

Viatris, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Gabapentinapproved, new study · Jan 31 · NCT07813026
·····

Viatris, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. selatogrelphase 3 · Jul 0 · NCT04957719
···
Pfizer37 readouts · 10 phase 3

Pfizer, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. rimegepantapproved, new study · Nov 29 · NCT06641466

Pfizer, Dec ’26: 8 programs whose next study reaches primary completion, 2 in phase 3

  1. ritlecitinibphase 3 · Dec 2 · NCT07029711
  2. vepdegestrantphase 3 · Dec 4 · NCT07231991
  3. VLA15phase 3 · Dec 4 · NCT07500506
  4. prifetrastatphase 3 · Dec 8 · NCT07721402
  5. disitamab vedotinphase 3 · Dec 11 · NCT04879329

and 3 more — sign in to see them all

Pfizer, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08653945phase 2 · Jan 13 · NCT07725809
  2. abrysvophase 3 · Jan 18 · NCT05035212
  3. berobenatidephase 3 · Jan 27 · NCT07508241

Pfizer, Feb ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. osivelotorphase 3 · Feb 8 · NCT06507904
  2. tilrekimigphase 3 · Feb 20 · NCT07792941
  3. PF-07328948phase 2 · Feb 23 · NCT07269301
  4. atirmociclibphase 3 · Feb 26 · NCT05262400
  5. mevrometostatphase 3 · Feb 28 · NCT06551324

Pfizer, Mar ’27: 3 programs whose next study reaches primary completion

  1. PG4phase 3 · Mar 4 · NCT06524414
  2. PF-08161842phase 1 · Mar 17 · NCT07897708
  3. PF-08103402phase 1 · Mar 30 · NCT07660731

Pfizer, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08642534phase 1 · Apr 21 · NCT07731139
  2. PG4 Multivalent Vaccinephase 3 · Apr 26 · NCT07794748

Pfizer, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abrocitinibphase 3 · May 2 · NCT06807268
  2. marstacimabphase 3 · May 5 · NCT06703606

Pfizer, Jun ’27: 3 programs whose next study reaches primary completion

  1. PF-07832837phase 1 · Jun 2 · NCT06564389
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3 · Jun 10 · NCT07023081
  3. sigvotatug vedotinphase 3 · Jun 16 · NCT04389632
·

Pfizer, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. elranatamabapproved, new study · Aug 4 · NCT05317416
  2. zavegepantphase 3 · Aug 12 · NCT06995729
  3. claturafenibphase 1 · Aug 31 · NCT05355701
  4. polfurmetinibphase 1 · Aug 31 · NCT05538130

Pfizer, Sep ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. PF-08065010phase 1 · Sep 1 · NCT07235163
  2. ibuzatrelvirphase 3 · Sep 28 · NCT07013474
  3. remdesivirphase 3 · Sep 28 · NCT07013474

Pfizer, Oct ’27: 3 programs whose next study reaches primary completion

  1. tivunatamigphase 3 · Oct 18 · NCT07227012
  2. PA-001phase 1 · Oct 21 · NCT07086677
  3. PG4 in Buffer 1 with low dose PA-002phase 1 · Oct 21 · NCT07086677
Yuhan10 readouts · 0 phase 3

Yuhan, Nov ’26: 3 programs whose next study reaches primary completion

  1. AD-234phase 1 · Nov 0 · NCT07717775
  2. AD-2341phase 1 · Nov 0 · NCT07717775
  3. AD-2342phase 1 · Nov 0 · NCT07717775
·

Yuhan, Jan ’27: 2 programs whose next study reaches primary completion

  1. YHP2508Bphase 1 · Jan 26 · NCT07912840
  2. YHR2602phase 1 · Jan 26 · NCT07912840

Yuhan, Feb ’27: 2 programs whose next study reaches primary completion

  1. YHP2508Aphase 1 · Feb 2 · NCT07912827
  2. YHR2601phase 1 · Feb 2 · NCT07912827

Yuhan, Mar ’27: 1 program whose next study reaches primary completion

  1. AD-211phase 2 · Mar 0 · NCT07550231
··

Yuhan, Jun ’27: 2 programs whose next study reaches primary completion

  1. YH32364phase 2 · Jun 0 · NCT06975410
  2. lesigerceptphase 2 · Jun 19 · NCT07415551
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Viatris

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Pfizer

New programs 6

Reached a new phase 0

None

Study stopped 3

  • PF-07868489phase 2 · terminated Nov 2 · none of its studies left running“The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” · NCT07073820
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. T…” · NCT05573555
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. Th…” · NCT06125522

Primary completion later 6

Yuhan

New programs 6

  • YHP2508Aphase 1 · first study · Oct 28
  • YHP2508Bphase 1 · first study · Oct 28
  • YHR2601phase 1 · first study · Oct 28
  • YHR2602phase 1 · first study · Oct 28
  • AD-233Aphase 3 · first study · Sep 7 · Diabetes Mellitus, Type 2
  • AD-233Bphase 3 · first study · Sep 7 · Diabetes Mellitus, Type 2

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 9 in all. A program counts in each condition its studies name most.

ConditionViatrisPfizerYuhan
Hypertension2 of 3 · compare here–

Pfizer in Hypertension: 1 program

  1. Prazosinphase 1

Their studies: Pfizer’s studies of Hypertension in search

Renal Insufficiency2 of 3 · compare here

Viatris in Renal Insufficiency: 1 program

  1. cenerimodphase 3

Their studies: Viatris’s studies of Renal Insufficiency in search

Pfizer in Renal Insufficiency: 4 programs

  1. prifetrastatphase 3
  2. abrocitinibphase 3
  3. osivelotorphase 3
  4. PF-07328948phase 2

Their studies: Pfizer’s studies of Renal Insufficiency in search

–
Asthma2 of 3 · compare here

Viatris in Asthma: 1 program

  1. Alprazolamapproved, new study

Their studies: Viatris’s studies of Asthma in search

Pfizer in Asthma: 3 programs

  1. tilrekimigphase 3
  2. zavegepantphase 3
  3. PF-08103402phase 1

Their studies: Pfizer’s studies of Asthma in search

–
Diabetes Mellitus, Type 22 of 3 · compare here–

Pfizer in Diabetes Mellitus, Type 2: 2 programs

  1. berobenatidephase 3
  2. danuglipronphase 2

Their studies: Pfizer’s studies of Diabetes Mellitus, Type 2 in search

Yuhan in Diabetes Mellitus, Type 2: 2 programs

  1. AD-233Aphase 3
  2. AD-233Bphase 3

Their studies: Yuhan’s studies of Diabetes Mellitus, Type 2 in search

Lupus Erythematosus, Systemic2 of 3 · compare here

Viatris in Lupus Erythematosus, Systemic: 1 program

  1. cenerimodphase 3

Their studies: Viatris’s studies of Lupus Erythematosus, Systemic in search

Pfizer in Lupus Erythematosus, Systemic: 2 programs

  1. dazukibartphase 3
  2. PF-08154225phase 2

Their studies: Pfizer’s studies of Lupus Erythematosus, Systemic in search

–
Chronic Urticaria2 of 3 · compare here–

Pfizer in Chronic Urticaria: 1 program

  1. ritlecitinibphase 3

Their studies: Pfizer’s studies of Chronic Urticaria in search

Yuhan in Chronic Urticaria: 1 program

  1. lesigerceptphase 2

Their studies: Yuhan’s studies of Chronic Urticaria in search

Diabetes Mellitus2 of 3 · compare here–

Pfizer in Diabetes Mellitus: 1 program

  1. danuglipronphase 2

Their studies: Pfizer’s studies of Diabetes Mellitus in search

Yuhan in Diabetes Mellitus: 1 program

  1. AD-123phase 1

Their studies: Yuhan’s studies of Diabetes Mellitus in search

Heart Failure2 of 3 · compare here–

Pfizer in Heart Failure: 1 program

  1. PF-07328948phase 2

Their studies: Pfizer’s studies of Heart Failure in search

Yuhan in Heart Failure: 1 program

  1. AD-118phase 1

Their studies: Yuhan’s studies of Heart Failure in search

Neoplasm Metastasis2 of 3 · compare here–

Pfizer in Neoplasm Metastasis: 1 program

  1. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Neoplasm Metastasis in search

Yuhan in Neoplasm Metastasis: 1 program

  1. YH32364phase 2

Their studies: Yuhan’s studies of Neoplasm Metastasis in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetViatrisPfizerYuhan
S1PR1cenerimodruleetrasimodrule–
A target, or a pathogen for a vaccine, known for: Viatris 4 of 6 · Pfizer 67 of 91 · Yuhan 1 of 53 programs (22 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Pfizer: 9).